Healthcare ❯ Regulatory Affairs ❯ FDA Approvals

Drug Development

TECVAYLI Clinical Trials Tolebrutinib Prader-Willi Syndrome Cutaneous T-cell Lymphoma Pompe Disease

Angelini Pharma to Acquire Catalyst Pharmaceuticals for $4.1 Billion in Cash

The all-cash deal gives the Italian group a U.S. foothold to scale a Brain Health–focused rare-disease platform.

Stories older than 24h

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

BioMarin to Acquire Amicus for $4.8 Billion in Cash